cdri 85-287 has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arshad, M; Ghosh, R; Sawlani, V; Sengupta, S; Sharma, S; Singh, MM | 1 |
| Blair, HC; Jordan, SE; McDonald, JM; McKenna, MA; Radding, W; Williams, JP | 1 |
2 other study(ies) available for cdri 85-287 and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator.
Topics: Animals; Autopsy; Benzopyrans; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Calcium; Centchroman; Chick Embryo; Densitometry; Disease Models, Animal; Epithelial Cells; Ethinyl Estradiol; Female; Femur; Osteocalcin; Osteoporosis; Ovary; Parathyroid Hormone; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Tibia | 2004 |
Differential effects of tamoxifen-like compounds on osteoclastic bone degradation, H(+)-ATPase activity, calmodulin-dependent cyclic nucleotide phosphodiesterase activity, and calmodulin binding.
Topics: Animals; Anticarcinogenic Agents; Benzopyrans; Bone Resorption; Calmodulin; Centchroman; Cyclic Nucleotide Phosphodiesterases, Type 1; Dose-Response Relationship, Drug; Female; Osteoclasts; Phosphoric Diester Hydrolases; Piperidines; Proton-Translocating ATPases; Tamoxifen; Trifluoperazine | 1997 |